Enzyme inhibitors and enzyme substrates

S- (+)-Rolipram.

S- (+)-Rolipram.

S- (+)-Rolipram.

Potent, selective p38 MAPK inhibitor: orally active.

Potent, selective p38 MAPK inhibitor: orally active.

Potent, selective p38 MAPK inhibitor: orally active.

Potent, selective p38 MAPK inhibitor: orally active.

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.MDCK cells were treated with SB 203580 to study the role of MAPK

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.MDCK cells were treated with SB 203580 to study the role of MAPK

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.MDCK cells were treated with SB 203580 to study the role of MAPK

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.MDCK cells were treated with SB 203580 to study the role of MAPK

SB 216763SB-216763 was used to inhibit GSK-3β in human brain microvascular endothelial cell line6and colorectal cancer cells.7SB-216763 was used to inhibit GSK-3β in human brain microvascular endothelial cell line and colorectal cancer cells.